

Name	David Chi-Leung <u>LAM</u>	
Country	Hong Kong SAR, China	
Organization	Department of Medicine, University of Hong Kong	
Current Position	Clinical Associate Professor	

Educational Background

1993	BSc (Biomed Sc) (Hon) (HK)	Department of Pathology, University of Hong Kong (HKU)
1995	MBBS (HK)	Faculty of Medicine, HKU
1999	MRCP (UK)	Member of the Royal College of Physicians, UK
2002	FHKCP	Fellow of the Hong Kong College of Physicians, HK
2002	FHKAM (Medicine)	Fellow of the Hong Kong Academy of Medicine, HK
2005	FCCP	Fellow of the American College of Chest Physicians, USA
2007	PhD (HK)	Molecular Pathology, Department of Pathology, HKU
2008	FACP	Fellow of the American College of Physicians, USA
2010	FRCP (Edinburgh)	Fellow of the Royal College of Physicians of Edinburgh, UK
2012	FRCP (Glasgow)	Fellow of the Royal College of Physicians and Surgeons at Glasgow, UK
2013	FAPSR	Fellow of the Asian Pacific Society of Respiriology
2014	MD (HK)	Faculty of Medicine, HKU
2017	FRCP (London)	Fellow of the Royal College of Physicians of London

Professional Experiences

Current appointments:

12.2017 – present	Clinical Associate Professor, Department of Medicine, HKU
12.2017 – present	Honorary Consultant, Department of Medicine, Queen Mary Hospital (QMH)
4.2022 – present	Chief of Division of Respiratory Medicine, Department of Medicine, HKU
7.2022 – present	Deputy Chief of Service (Service Planning), Department of Medicine, QMH
7.2014 – present	Honorary Consultant, Department of Medicine, HKU-Shenzhen Hospital

Honors and Awards

1	The Asian-Pacific Society of Respiriology (APSR) Woolcock Research Award	2021
2	Tohoku Medical Society Medal, Tohoku University, Sendai, Japan	2019
3	Sir Patrick Manson Gold Medal, Faculty of Medicine, University of Hong Kong	2014
4	Faculty Teaching Medal, Faculty of Medicine, University of Hong Kong	2013
5	APSR Travel Award to attend American Thoracic Society (ATS) Annual Conference	2010
6	Travel Award, 14 th Congress of the APSR	2009
7	AACR ITO-EN Ltd Scholar-in-training Award, American Association of Cancer Research (AACR)	2005
8	Japanese Respiratory Society Young Investigator Award	2005
9	Young Investigator Award (Cancer – Basic Science Group) Medical Research Conference, HKU	2004
10	The International Association on Study of Lung Cancer (IASLC) Young Investigator Award	2003
11	The Hong Kong Lung Foundation Fellowship	2002-03
12	The Hong Kong Thoracic Society Young Investigator Award	2002

Professional Organizations

President (2021 - present)	Asian Pacific Society of Respirology (APSR)
President (2022)	Forum of International Respiratory Societies (FIRS)
Deputy Head (2021 - present)	Lung Cancer Assembly, Asian Pacific Society of Respirology (APSR)
Deputy Editor:	<i>Respirology</i> 2015 – present
Associate Editor:	<i>Respirology</i> 2012 – 2014; <i>Respirology Case Reports</i> 2014 – present
Committee member (2019 – present)	Screening and Early Detection Committee, IASLC
Co-Chairperson (2020 – present)	East Asian Lung Cancer Screening Alliance, Lung Ambition Alliance, IASLC
Board Member (2013 – present)	Hong Kong Lung Foundation

Main Scientific Publications

Selected representative publications in recent years (**= corresponding author)

1. Kwok HH, Li H, Yang J, Deng J, Lee NC, Au TW, Sit AK, Hsin MK, Ma SK, Cheung LW, Girard L, Fujimoto J, Wistuba II, Gao B, Minna JD, **Lam DC****.
Single-cell transcriptomic analysis uncovers intratumoral heterogeneity and drug-tolerant persister in ALK-rearranged lung adenocarcinoma. *Cancer Commun (Lond)*. 2023 Jun 4. (in press)
2. Tammemägi MC, Ruparel M, Tremblay A, Myers R, Mayo J, Yee J, Atkar-Khattra S, Yuan R, Cressman S, English J, Bedard E, MacEachern P, Burrowes P, Quaife SL, Marshall H, Yang I, Bowman R, Passmore L, McWilliams A, Brims F, Lim KP, Mo L, Melsom S, Saffar B, Teh M, Sheehan R, Kuok Y, Manser R, Irving L, Steinfors D, McCusker M, Pascoe D, Fogarty P, Stone E, **Lam DCL**, Ng MY, Vardhanabhuti V, Berg CD, Hung RJ, Janes SM, Fong K, Lam S.
USPSTF2013 versus PLCom2012 lung cancer screening eligibility criteria (International Lung Screening Trial): interim analysis of a prospective cohort study. *Lancet Oncol*. 2022 Dec 10;S1470-2045(21)00590-8.
3. Kwok HH, Gao B, KH Chan, Ip MS, Minna JD, **Lam DC****.
Nicotinic acetylcholine receptor subunit alpha 7 mediates cigarette smoke-induced PD-L1 expression in human bronchial epithelial cells.
Cancers 2021 Oct 25;13(21):5345.
4. Ho GYF, Wang T, Kwok HH, Rasul R, Peila R, Guzman M, Ip MSM, **Lam DCL****. Longitudinal multi-gene panel assessment of circulating tumor DNA revealed tumor burden and molecular characteristics along treatment course of non-small cell lung cancer.
Transl Lung Cancer Res 2020 Oct; 9(5):1873-1884.
5. Luo SY, Kwok HH, Yang PC, Ip MS, Minna JD, **Lam DC****.
Expression of large tumour suppressor (LATS) kinases modulates chemotherapy response in advanced non-small cell lung cancer.
Transl Lung Cancer Res 2020 Apr; 9(2): 294-305.
6. Kwok HH, Ning Z, Chong PW, Wan TS, Ng MH, Ho GY, Ip MS, **Lam DC****.
Transfer of extracellular vesicle-associated-RNAs induces drug resistance in ALK-translocated lung adenocarcinoma.
Cancers 2019; Jan 17;11(1). pii: E104

Other selected publications

7. Liam CK, Stone E, Andarini S, Liam YS, **Lam DC**, Lee P. Molecular testing of metastatic non-small cell lung cancer in the Asia-Pacific region. *Respirology*. 2020 Jul;25(7):685-687.
8. Chiang KY, Ho JC, Chong P, Tam TC, **Lam DC**, Ip MS, Lee YG, Lui MM. Role of early definitive management for newly diagnosed malignant pleural effusion related to lung cancer. *Respirology* 2020 Apr 6.

9. Kwok WC, Cheong TF, Chiang KY, Ho JC, **Lam DC**, Ip MS, Tam TC. Haematological toxicity of pemetrexed in patients with metastatic non-squamous non-small cell carcinoma of lung with third-space fluid. *Lung Cancer* 2020 Dec 4; 152:15-20.
10. Lim KP, Marshall H, Tammemägi M, Brims F, McWilliams A, Stone E, Manser R, Canfell K, Weber M, Connelly L, Bowman RV, Yang IA, Fogarty P, Mayo J, Yee J, Myers R, Atkar-Khattra S, **Lam DC**, Rosell A, Berg CD, Fong KM, Lam S; International Lung Screening Trial (ILST) Investigators. Protocol and rationale for the International Lung Screening Trial (ILST). *Ann Am Thorac Soc*. 2020 Feb 3, 17(4), 503–512.
11. Chang GC, **Lam DC**, Tsai CM, Chen YM, Shih JY, Aggarwal S, Wang S, Kim SW, Kim YC, Wahid I, Li R, Lim DW, Sriuranpong V, Chan RT, Lorence RM, Carriere P, Raabe C, Cseh A, Park K. Experience from Asian centers in a named-patient-use program for afatinib in patients with advanced non-small-cell lung cancer who had progressed following prior therapies, including patients with uncommon EGFR mutations. *Int J Clin Oncol*. 2021 May;26(5):841-850.
12. Tu HY, Feng J, Shi M, Zhao J, Wang Y, Chang J, Wang J, Cheng Y, Zhu J, Tan EH, Li K, Zhang Y, Lee V, Yang CT, Su WC, **Lam DC**, Srinivasa BJ, Rajappa S, Ho CL, Lam KC, Hu Y, Bondarde SA, Liu X, Tian Y, Xue Z, Cseh A, Huang DC, Zhou C, Wu YL. A Phase IIIb Open-Label, Single-Arm Study of Afatinib in EGFR TKI-Naïve Patients with EGFRm+ NSCLC: Final Analysis, with a Focus on Patients Enrolled at Sites in China. *Target Oncol*. 2022 Jan 12.
13. Fong KM, Marshall HM, **Lam DC**. Lung cancer screening-Marching along ... *Respirology* 2022 May 17.
14. **Lam DC****. World Lung Day 2022 – Lung Health for All. *Respirology* 2022 Oct;27(10):810-811.
15. Li X, Peng K, Cheng FWT, **Lam DCL**, Cheung CL, Chui CSL, Lai FTT, Wan EYF, Wong CKH, Ma T, Yum SHH, Chan EWY, Huang JD, Lau CS, Ip MSM, Wong ICK. Tuberculosis following two-dose SARS-CoV-2 vaccination with messenger RNA vaccine (BNT162b2) and inactivated virus vaccine (CoronaVac). *J Infect*. 2022 Dec 17:S0163-4453(22)00706-X.
16. Kwok HH, Yang J, **Lam DC****. Breaking the Invisible Barriers: Unleashing the Full Potential of Immune Checkpoint Inhibitors in Oncogene-Driven Lung Adenocarcinoma. *Cancers* (Basel). 2023 May 13;15(10):2749.
17. Berg CD, Schiller JH, Boffetta P, Cai J, Connolly C, Kerpel-Fronius A, Kitts AB, **Lam DCL**, Mohan A, Myers R, Suri T, Tammemägi MC, Yang D, Lam S; IASLC Early Detection and Screening Committee. AIR POLLUTION AND LUNG CANCER A Review by International Association for the Study of Lung Cancer Early Detection and Screening Committee. *J Thorac Oncol*. 2023 Jun 3:S1556-0864(23)00601-9. (In press).
18. **Lam DC**, Liam CK, Andarini S, Park S, Tan DSW, Singh N, Jang SH, Vardhanabhuti V, Ramos AB, Nakayama T, Nhung NV, Ashizawa K, Chang YC, Tscheikuna J, Van CC, Chan WY, Lai YH, Yang PC. Lung Cancer Screening in Asia: An Expert Consensus Report. *J Thorac Oncol*. 2023 Jun 28:S1556-0864(23)00635-4.

Book Chapter

Lam DC, Nakanishi Y, Fukuchi Y. Chapter 4. Future health challenges; climate, pollution, population impacts on respiratory health and lung cancer. In: Marinez-Garcia MA, Gaga M, Fong KM, eds. Lung Diseases and Cancer (*ERS Monograph*). Sheffield, European Respiratory Society 2022; pp. 48 – 58.